Mammoptix
Open bankruptcyA bankruptcy procedure is open for Mammoptix according to publications in the Belgian State Gazette; curator: FILIP SELS.
Summary
The file additionally contains 1 administrative flag. The 2023 annual accounts show negative equity (€-76k) and a net result of €-126k.
Signals
Three signals. The signal on the left, the evidence on the right.
+raises risk
raises risk · Administrative warnings in the KBO publications
1 publication by the FPS Economy about this company, such as a strike-off for address, accounts or UBO, or its withdrawal.
KBO publicationsPublications
Address struck
Financials · fiscal year 2023, micro schema
Equity
€-76k
Total assets
€38k
Net result
€-126k
Working capital
€-102k
Turnover and EBIT margin not published: the micro schema does not require them.
Balance-sheet composition
Assets €38k
Fixed assets
€26k
Current assets
€12k
Key figures and ratios
EBITDA
€-121k
Cash flow
€-123k
Solvency
-199.3%
Current ratio
0.10
Debt to equity
-1.50
ROA
-330.7%
Interest coverage
-58.26
Debt
€114k
Debt ≤ 1 year
€114k
Staff costs
€159
Filed annual accounts As filed with the NBB · 2023 · 30 lines
Balance sheet
Code2023
Assets
Total assets20/58€38k
Fixed assets21/28€26k
Intangible fixed assets21€26k
Current assets29/58€12k
Amounts receivable within one year40/41€12k
Other amounts receivable41€12k
Cash at bank and in hand54/58€8
Equity and liabilities
Total equity and liabilities10/49€38k
Equity10/15€-76k
Contributions10/11€50k
Outside capital11€50k
Share premium1100/10€50k
Profit (loss) carried forward14€-126k
Amounts payable17/49€114k
Amounts payable within one year42/48€114k
Trade debts44€34k
Suppliers440/4€34k
Other amounts payable47/48€80k
Income statement
Code2023
Remuneration, social security and pensions62€159
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€3k
Gross operating margin9900€-120k
Operating profit (loss)9901€-124k
Financial income75/76B€7
Recurring financial income75€7
Financial charges65/66B€2k
Recurring financial charges65€2k
Profit (loss) for the period before taxes9903€-126k
Profit (loss) for the period9904€-126k
Profit (loss) for the period to be appropriated9905€-126k
Appropriation of the result
Profit (loss) to be appropriated9906€-126k
The notes to these accounts (4 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
2026
20-08
Bankruptcy
Opening
Ondernemingsrechtbank Antwerpen, afdeling Antwerpen · MAMMOPTIX BV NIJVER- HEIDSSTRAAT 70, 2160 WOMMELGEM · event 13-08-2026
2025
23-05
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema · 296 days late
2024
02-08
KBO administration
Address struck
SignalNBB filing
Directors · office · real estate
Directors
2 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
1 establishment unit since 2022
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Ground area
1.0 ha
Building footprint
2,289 m²
Volume, LiDAR
25,507 m³
Parcel 11052C0585/00T002, Flanders · tallest building 14.7 m, ±4 floors. Linked by address, not a title deed.
1 establishment unit
Mammoptix
since 20222.332.904.438
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 11052C0585/00T002 | Flanders | 1.0 ha | 1 · 2,288 m² | 14.7 m · 4 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Insolvency mandates
1 mandate| Role | Name | Tenure |
|---|---|---|
| Curator | FILIP SELS HEMELSTRAAT 3, 2018 ANTWERPEN 1- |
13-08-2026 → present |
Public money · subsidies and aid
Flemish government
2022 to 2024 · 5 entries · 57,500 EUR awarded · 57,500 EUR paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2024 | 1 | -175,313 EUR | 0 EUR |
| 2023 | 2 | 175,313 EUR | 25,000 EUR |
| 2022 | 2 | 57,500 EUR | 32,500 EUR |
Schemes
O&O-haalbaarheidsstudie
Subsidie voor opleiding en advies voor kmo's en zelfstandigen (kmo-portefeuille)
Ontwikkelingsproject
Similar companies · same sector and region
ALDENT
BE 0422.727.681
Antwerpen
ARCA & JUNCO ASSOCIES
BE 0424.140.418
Sint-Lambrechts-Woluwe
BELGIAN OPTICAL SUPPLY
BE 0405.585.803
Kuurne
BELIV
BE 0423.599.097
Haaltert
Berthold Technologies (Belgium)
BE 0414.444.871
Vilvoorde
This company's figures show no positive equity and no headcount, so a size comparison is not possible. These companies share only the sector and the region. Of 1,249 companies in sector 32500 we hold annual accounts for 694. See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded01-06-2022
Fiscal year end31-12
Activities, NACEBEL 2025
32500Manufacture of medical and dental instruments and supplies
Sources
Crossroads Bank for EnterprisesNational Bank · 1 filingAddress and cadastre registers
Scores and ratios are computed by Checked and are not a credit decision.
Contact details
2 entriesWebsite:www.mammoptix.com
E-mail:info@mammoptix.com